JP4255316B2 - Functional carrier and functional material using the same - Google Patents

Description

[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a functional carrier and a functional material using the same.
[0002]
[Prior art]
Conventionally, as a method of visually recognizing the volatilization state of a liquid medicine having some effect carried on a carrier by color change, the following methods can be mentioned.
First, a mixture of a compound having a phenolic hydroxyl group, an electron-donating colored organic compound that develops color in the presence thereof, and a liquid organic compound that has a desensitizing effect on the coloring of the electron-donating colored organic compound. As the liquid organic compound having the desensitizing action is volatilized, the electron-donating colored organic compound is colored to change the volatilization state of the liquid organic compound having the desensitizing action. A method of visually recognizing is described in Patent Document 1.
[0003]
In addition, a solution in which a non-volatile oil-soluble dye is dissolved in a room temperature volatile organic compound is held in an oil-absorbing carrier, and the non-volatile oil-soluble dye dissolved in the vaporization of the room temperature volatile organic compound is Patent Document 2 describes a method of visually recognizing the volatilization state of the room temperature volatile organic compound by condensing and losing its color and clarifying the color of the oil-absorbing carrier.
[0004]
In addition, a paper-like body consisting of an oil-permeable substrate material exhibiting a base color and an oil-permeable, low refractive index ground color layer formed on one or both sides of this substrate material is a room temperature liquid volatile and oil-based material. By adding the insect repellent, the ground color layer is made transparent to exhibit the color of the substrate material, and then the color of the ground color layer appears along with the volatilization of the insect repellent and the color of the substrate material is changed. Patent Document 3 describes a method for visually recognizing the volatilized state of the insect repellent by making it invisible.
[0005]
[Patent Document 1]
JP-A-2-290592 [Patent Literature 2]
JP-A-6-116544 [Patent Document 3]
JP 60-224603 A [0006]
[Problems to be solved by the invention]
However, the method described in Patent Document 1 requires that the liquid organic compound itself exhibiting the required effect has a desensitizing action. For this reason, depending on the properties of the liquid organic compound, it may not be used.
[0007]
In addition, the method described in Patent Document 2 shows that when the room temperature volatile organic compound is volatilized, depending on the combination of the oil-absorbing carrier, the room temperature volatile organic compound, and the non-volatile oil-soluble pigment, The oil-soluble pigment may not fully condense and its color may not disappear clearly.
[0008]
Further, the method described in Patent Document 3 does not have the disadvantages as the methods described in Patent Document 1 and Patent Document 2, but the above-mentioned insecticide is used because the paper-like body is thin. It is difficult to apply unless the amount of the insect repellent is small and the amount of the insect repellent is sufficient. For example, when a large amount of medicine such as a fragrance or a deodorant is required, the preparation becomes unnecessarily large, which is not suitable.
[0009]
Therefore, the present invention can be applied regardless of the nature of the volatile liquid drug, the volatilization state of the drug can be clearly seen as a color change, the drug product can be compact even if the drug amount is large, and the carrier is easy to handle. The purpose is to provide functional materials.
[0010]
[Means for Solving the Problems]
The present invention solves the above problem by using a functional carrier provided with a coating layer containing a fine powder of a transparent material on the surface of a porous granular base material, and a functional material carrying a volatile liquid drug thereon. It was solved.
[0011]
In the initial stage where the liquid drug is volatilized, the coating layer of the functional carrier contains the liquid drug, thereby increasing the translucency of the coating layer and changing the color of the porous granular substrate from the outside. It can be visually recognized. After that, due to the volatilization of the drug, the liquid drug contained in the coating layer is reduced, the translucency of the coating layer is lowered, and the color of the porous granular substrate becomes invisible, and the functional carrier The color becomes visible as white due to diffuse reflection. The volatilization state of the liquid drug can be confirmed by this color change.
[0012]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
[0013]
The functional carrier 4 according to the present invention is a granular body in which a coating layer 2 containing a fine powder of a transparent material is provided on the surface of a porous granular substrate 1. When the volatile liquid medicine 3 is supported on the functional carrier 4, the functional material 4 ′ is obtained.
[0014]
It is desirable that the porous granular base material 1 is porous and can sufficiently absorb the volatile liquid medicine 3. Moreover, in order to ensure ease of handling, a spherical shape is desirable.
[0015]
Examples of the porous granular substrate 1 include granular foams such as regenerated cellulose, polyvinyl alcohol, and polyurethane, natural fibers such as pulp, or granules of synthetic fibers such as acrylic resin and polypropylene, and activated carbon. And aggregates of fine particles such as zeolite and alumina. Among these, it is particularly desirable that the main component is a cellulose material such as a foam of regenerated cellulose or a granulated product of pulp fibers, from the viewpoint of stability, supporting ability, and discardability with respect to the volatile liquid medicine 3.
[0016]
The porous granular substrate 1 is preferably colored. It is more desirable that it is colored with a highly saturated color such as red or blue or a clear color such as black. Since the end of volatilization is visually recognized by the change from the color of the porous granular base material 1 indicated by the functional material 4 ′ to white, the color of the porous granular base material 1 is a color close to white or gray. There is a risk that it is difficult to detect the color change.
[0017]
The particle size of the porous granular substrate 1 is preferably 0.1 to 30 mm, more preferably 1 to 10 mm. If the particle size is less than 0.1 mm, the apparent surface area per unit weight becomes too large, and the required amount of the fine powder used for coating may be too large. Moreover, it becomes difficult to handle as a carrier. On the other hand, when the particle size exceeds 30 mm, the volatile liquid drug 3 contained in the deep part of the porous granular base material 1 is slow to come out on the surface, and the drug still remains inside the base material. Despite being present, the surface may be whitened first.
[0018]
Moreover, the specific gravity of the porous granular substrate 1 is not particularly limited, but it is desirable that the porous granular substrate 1 be lightweight as long as the execution of the present invention is not hindered.
[0019]
The porosity of the porous granular substrate is desirably 60 to 97%. If the porosity is less than 60%, there is a possibility that a sufficient amount of drug loaded cannot be secured. On the other hand, if the porosity exceeds 97%, the strength of the carrier becomes weak and it may be difficult to use it as a functional carrier.
[0020]
Furthermore, the porous granular substrate 1 is desirably high in strength, but is not particularly limited as long as it does not hinder the execution of the present invention.
[0021]
The transparent material is a material having transparency or translucency, and is more desirable as it is colorless and highly transparent. The powder is desirably white in appearance. Examples of such a transparent material include silicic acid, calcium silicate, aluminum silicate, gypsum, kaolin, and pulp powder. In particular, silicic acid, calcium silicate, aluminum silicate, or a mixture thereof is more desirable.
[0022]
In addition, it is desirable to select a material having a refractive index close to that of the volatile liquid drug 3. When the refractive index is close, it is difficult to diffusely reflect at the boundary between the transparent material and the volatile liquid medicine 3, and the light hν easily passes through the coating layer 2 containing the volatile liquid medicine 3, It is easy to exhibit the color of the porous granular base material 1 in.
[0023]
The fine powder of the transparent material preferably has a particle size of 0.01 to 50 μm, more preferably 0.1 to 30 μm. When the particle size is less than 0.01 μm, handling becomes difficult and the production cost may increase. On the other hand, when the particle diameter exceeds 50 μm, the concealing effect is low, and thus the color of the porous granular substrate 1 may not be concealed.
[0024]
Since it is difficult to fix only the transparent material to the porous granular substrate 1, it is easy to fix the porous granular substrate 1 by mixing a binder with the transparent material, and The porous granular substrate 1 is coated to form the coating layer 2. In FIG. 1, no binder is displayed.
[0025]
Examples of the binder include urethane resins, acrylic ester resins, polycarbonate resins, vinyl acetate resins, styrene-butadiene copolymer resins, vinyl chloride-vinyl acetate copolymer resins, and resins selected from these. Emulsions, cellulose derivatives, polyvinyl alcohol and derivatives thereof, casein, starch, and the like can be used. In particular, emulsions of the above urethane resins and acrylic ester resins are desirable because they are excellent in bond strength and handleability. When chemical resistance and solvent resistance are required, polyvinyl alcohol and its derivatives are desirable.
[0026]
The urethane-based resin refers to a polymer having a urethane bond, and examples thereof include a polyester-based urethane resin, a polyether-based urethane resin, and a polycarbonate-based urethane resin. The acrylic ester resin refers to a polymer obtained by homopolymerizing or copolymerizing the acrylic ester. The polycarbonate-based resin refers to a resin mainly composed of polycarbonate, and examples thereof include polycarbonate / acrylonitrile / butadiene / styrene alloy and polycarbonate / polystyrene alloy.
[0027]
Moreover, the said polyvinyl alcohol and its derivative (s) means the high molecular compound obtained by saponifying polyvinyl acetate with an alkali, an acid, ammonia water, etc., and what chemically modified this. Although not particularly limited, it is desirable that the polymerization degree is 300 to 3000 and the saponification degree is 80 to 100%.
[0028]
The blending ratio of the binder and the transparent material that forms the coating layer 2 is preferably such that the fine powder of the transparent material is 20 to 2000 parts by weight with respect to 100 parts by weight of the binder. If it is -1000 weight part, it is more desirable. If the amount of the fine powder of the transparent material is less than 20 parts by weight, the amount of the transparent material is too small, the concealability is lowered, and the change in the color of the functional carrier 4 may be difficult to visually recognize. Moreover, the permeability with respect to the volatile liquid drug 3 is also lowered, and the functional carrier 4 may be difficult to support the volatile liquid drug 3. On the other hand, when the amount exceeds 2000 parts by weight, there is a possibility that the binder is insufficient and cannot be sufficiently fixed. In addition to the above-described transparent material and binder, auxiliary agents such as a resin cross-linking agent and a thickener may be added as necessary.
[0029]
Examples of the method for providing the coating layer 2 on the surface of the porous granular substrate 1 include impregnation, coating, spraying by spraying, fluidized bed coating method, and the like. In particular, the fluidized bed coating method is preferable because of high manufacturing efficiency and uniformity of the coating layer 2 to be formed. The fluidized bed coating method is a method in which a dispersion liquid of the fine powder of the transparent material and the binder is attached to the porous granular substrate 1 while fluidly drying the porous granular substrate 1. .
[0030]
The thickness of the coating layer 2 provided by these methods is preferably 0.5 to 500 μm, and more preferably 1 to 100 μm. When the thickness is less than 0.5 μm, the concealing property becomes insufficient, and the color of the porous granular base material 1 remains exhibited even when the volatile liquid drug 3 is not contained. Changes may not be visible. On the other hand, when the thickness exceeds 500 μm, the transparency is insufficient, and even if the volatile liquid medicine 3 is carried, the color of the base material may not be exhibited.
[0031]
The color of the coating layer 2 is basically white due to irregular reflection by a fine powder of a transparent or translucent material, but the difference from the porous granular substrate 1 is clear. It may be colored in a color that can be understood.
[0032]
The said volatile liquid chemical | medical agent 3 says what is a liquid under normal temperature normal pressure, and has volatile property. For example, a solvent having a function such as a solvent such as water or a fragrance, a deodorant, an insect repellent, a bactericidal agent, and an antibacterial / antifungal agent can be used.
[0033]
By forming the coating layer 2 with the fine powder of the transparent material, the functional material 4 ′ in which the coating layer 2 contains the volatile liquid drug 3 has the fine powder, the volatile liquid drug 3, and the like. The functional material 4 ′ exhibits the color of the porous granular base material 1 under the coating layer 2 because the light hν is less likely to be diffusely reflected and easily transmitted at the boundary. On the other hand, the volatile liquid drug 3 is reduced to some extent by volatilization, and the functional material 4 ′ approaching the functional carrier 4, or the functional carrier 4 itself containing no volatile liquid drug 3 at all. In the coating layer 2, since the light hν is diffusely reflected at the boundary between air and the fine powder, the color of the porous granular base material 1 is concealed and white in appearance. The volatilization state of the volatile liquid drug 3 can be visually recognized by the color change from the color of the porous granular substrate 1 to white.
[0034]
【Example】
Hereinafter, the present invention will be specifically described by way of examples.
In addition, the detail of the chemical | medical agent used here is as follows.
-Fine powder silicic acid 1 (fine powder of the above transparent material)-Nippon Silica Kogyo Co., Ltd .: Nipgel AY401, particle size 4.1 μm
-Fine powder silicic acid 2 (fine powder of the above transparent material)-Nippon Silica Kogyo Co., Ltd .: Nipgel BY001, particle size 14 μm
[0035]
-Aqueous polyether urethane emulsion (binder)-Sanyo Chemical Industries, Ltd .: Permarin UA-150 Solid content 30%
・ Acrylate ester copolymer emulsion (binder) ・ Made by Johnson Polymer Co., Ltd .: Jonkrill 840 solid content 43%
[0036]
・ Ethyl alcohol ・ ・ Nacalai Tesque Co., Ltd. ・ Isopropyl alcohol ・ Nacalai Tesque Co., Ltd. ・ Turpineol ・ Nacalai Tesque Co., Ltd. ・ Limonene ・ Nacalai Tesque Co., Ltd. ・ Water-based resin cross-linking agent ・ Japan Polyurethane Industry Co., Ltd .: Aquanate AQ200
[0037]
-Blue colored cellulose particles (porous granular base material)-Rengo Co., Ltd. product: Visco Pearl AH-4050 particle size 4mm
-Black colored cellulose particles (porous granular base material)-Rengo Co., Ltd .: Viscopearl P CTA-4610 Particle size 4 mm
[0038]
( Comparative Example 1 )
As materials for the coating layer 2, 15 parts by weight of finely divided silicic acid 1, 50 parts by weight of aqueous polyether urethane emulsion, 10 parts by weight of ethyl alcohol, 2 parts by weight of aqueous resin cross-linking agent, and 50 parts by weight of water A coating solution was prepared as a part.
Using a fluidized bed granulation coating apparatus (Freund Sangyo Co., Ltd .: FL-MINI), the above coating liquid is coated on blue colored cellulose particles, and heated and cured at 80 ° C. for 30 minutes to obtain blue colored cellulose particles. White coated beads that blocked the blue color were obtained. The thickness of the coating layer of this coated bead was 20 μm.
[0039]
The coated beads (10 ml) obtained as described above were impregnated with the natural insect repellent terpineol (2 g), which is the volatile liquid drug, so that the coated beads exhibited the blue color of blue colored cellulose particles. .
The coated beads were wrapped with a drug-permeable packaging material to obtain a wrapping insecticide.
[0040]
When the terpineol contained in the coating beads was volatilized from the insect repellent, the coating beads turned from blue to white when 90% was volatilized, and the function of displaying the volatilization state of the drug was exhibited.
[0041]
( Comparative Example 2 )
As materials for the coating layer 2, 15 parts by weight of finely divided silicic acid 2, 15 parts by weight of an acrylate copolymer emulsion, 10 parts by weight of isopropyl alcohol, 2 parts by weight of an aqueous resin crosslinking agent, and 60 parts by weight of water A coating solution was prepared as a part.
Using the fluidized bed granulation coating device (Freund Sangyo Co., Ltd .: FL-MINI), the above coating liquid is coated on black colored cellulose particles to obtain white coated beads that block the black color of the black colored cellulose particles. It was. The thickness of the coating layer of this coated bead was 80 μm.
[0042]
The coated beads (10 ml) obtained as described above were impregnated with the fragrance limonene (2 g), which is the volatile liquid drug, so that the coated beads exhibited the black color of the black colored cellulose particles.
The coated beads were put in a polypropylene case having an opening to obtain a preparation having aroma performance.
[0043]
When the limonene contained in the coating beads is volatilized from the preparation with the above-mentioned fragrance performance, the coating beads change color from black to white when 80% is volatilized, and the function of displaying the volatilization state of the drug is exhibited. did.
[0044]
【The invention's effect】
With the functional carrier and the functional material according to the present invention, the end time of the effect of volatilization of the preparation using the volatile liquid drug can be clearly recognized as a color change.
[Brief description of the drawings]
FIG. 1 is a schematic diagram of a functional carrier according to the present invention. FIG. 2 is a schematic diagram of a functional material according to the present invention.
1 Porous granular substrate 2 Coating layer (binder not shown)
3 Volatile liquid medicine 4 Functional carrier 4 'Functional material hν Light

Claims (6)

A functional carrier in which a coating layer containing a fine powder made of a transparent material and having a white appearance is formed on a surface of a porous granular substrate with a binder which is polyvinyl alcohol or a derivative thereof .   The functional carrier according to claim 1, wherein the porous granular substrate is a porous granular material composed mainly of cellulose.   The functional carrier according to claim 1 or 2, wherein the transparent material comprises at least one of silicic acid, aluminum silicate, and calcium silicate. The functional material which made the functional support | carrier in any one of Claims 1 thru | or 3 carry | support a volatile liquid chemical | medical agent. When the functional carrier according to any one of claims 1 to 3 is produced, a dispersion liquid of the fine powder of the transparent material and the binder is dispersed in the porous material while fluidly drying the porous granular substrate. A method for producing a functional carrier, wherein the coating layer is produced by adhering to a surface of a granular substrate. The manufacturing method of a functional material which makes a functional carrier manufactured by the manufacturing method of Claim 5 carry | support a volatile liquid chemical | medical agent.

Images